( January 21, 2026, 23:39 GMT | Official Statement) -- MLex Summary: The US Federal Trade Commission's in-house enforcement action against pharmacy benefit managers Caremark Rx, Express Scripts, OptumRx and their affiliated group purchasing organizations over allegedly inflated insulin prices has been stayed for two weeks pending consideration of a proposed consent decree between the agency and some parties, an FTC administrative law judge said in an order. Oral argument on motions to dismiss from the PBMs and others has been rescheduled to Feb, 5, the order said.See attached document....
Prepare for tomorrow’s regulatory change, today
MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.
Know what others in the room don’t, with features including:
- Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
- Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
- Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
- Curated case files bringing together news, analysis and source documents in a single timeline
Experience MLex today with a 14-day free trial.